본문으로 건너뛰기
← 뒤로

Medullary thyroid cancer - An update.

1/5 보강
Best practice & research. Clinical endocrinology & metabolism 2023 Vol.37(1) p. 101655
Retraction 확인
출처

Fugazzola L

📝 환자 설명용 한 줄

Medullary thyroid cancer (MTC) is a rare neuroendocrine disease, encompassing about 5% of all thyroid cancers.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Fugazzola L (2023). Medullary thyroid cancer - An update.. Best practice & research. Clinical endocrinology & metabolism, 37(1), 101655. https://doi.org/10.1016/j.beem.2022.101655
MLA Fugazzola L. "Medullary thyroid cancer - An update.." Best practice & research. Clinical endocrinology & metabolism, vol. 37, no. 1, 2023, pp. 101655.
PMID 35422397 ↗

Abstract

Medullary thyroid cancer (MTC) is a rare neuroendocrine disease, encompassing about 5% of all thyroid cancers. Due to its peculiar features, this rare tumour offers unique possibilities for translational research studies. It arises from neuroendocrine parafollicular cells in an endocrine organ, and appears as a nodule apparently indistinguishable from thyroid nodules. It has a very peculiar progression with micro metastases difficult to identify, often-remaining stable during years and suddenly undergoing a rapid and unrestrainable progression. Moreover, MTC is one of the neoplasms with the best genetic characterization either in its sporadic or familial form, providing a valuable background to test targeted drugs. In the era of precision medicine, this review aims to give an update on the diagnostic tools, the therapeutic options for advanced MTC, and the most promising opportunities for a personalized follow up.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반